Back to results
US 2024/0002800 A1Published application
Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
AssigneeMendus B.V.
InventorsAlex Karlsson-Parra, Erik Hans Manting, Haoxiao Zuo, Satwinder Kaur Singh
Life of this patent
Estimating the term…
Abstract
The present disclosure provides ex vivo methods which employ modified cells of leukemic origin to enhance the efficacy of adoptive cell therapy with natural killer (NK) cells.
Claims38
A method for activating, stimulating and and/or expanding natural killer (NK) cells, comprising:
- (a) contacting a population of immune cells substantially comprising natural killer (NK) cells with a population of modified cells of leukemic origin, wherein the modified cells exhibit a mature dendritic cell phenotype;
- and
- (b) co-culturing the population of immune cells with the modified cells of leukemic origin for a period of time such that the modified cell of leukemic origin activates the natural killer (NK) cells in the population of immune cells, thereby generating an expanded population of activated natural killer (NK) cells.
5-8. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
The method of claim 116 or claim 17, wherein the population of immune cells are:
- 1) isolated from peripheral blood mononuclear cells (PBMCs) of the subject;
- 2) derived from induced pluripotent stem cells (iPSCs) or cord blood;
- or
- 3) are isolated from peripheral blood mononuclear cells (PBMCs) of an allogeneic third-party donor different from a subject to receive the expanded population of activated NK cells, optionally wherein the third-party donor is positive for Cytomegalovirus (CMV+).
1 more element
19-21. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
32-35. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.